{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T17:42:07Z","timestamp":1788975727301,"version":"build-2803163510"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Hepatitis B virus (HBV) reactivation in patients with HBV\/hepatitis C virus (HCV) co-infection due to direct-acting antiviral agent (DAA) therapy is a growing concern. This study focused on 47 patients with chronic hepatitis C (CHC) and positivity for HBV surface antigen (HBsAg) who were treated with interferon (IFN)-based therapy, DAA, or DAA after IFN-based therapy failure and followed for a median of 53 months. Here, we aimed to determine HBV reactivation rates and associated factors, the incidence of HBV and liver-related events, and the rate of sustained virologic response (SVR) for HCV. Fifteen (15\/47, 31.9%) patients experienced HBV reactivation during or after HCV treatment. This reactivation occurred significantly more frequently in patients who received DAA treatment after IFN-based treatment failure than in those who received IFN-based treatment (IFN-based vs. DAA vs. DAA treatment after IFN-based treatment failure 11.8% vs. 35.3% vs. 53.8%, respectively; p\u2009=\u20090.046). The interval from HCV treatment initiation to HBV reactivation was shortest in the DAA group (4.2 months), followed by the DAA after IFN-based treatment failure group (6.4 months) and the IFN-based treatment group (44.5 months) (p\u2009&lt;\u20090.001). One case of HBV-related hepatitis spontaneously resolved after 4 weeks. The rate of SVR for the entire cohort was 87.2%, with no significant difference in this regard among the IFN-based treated, DAA-treated, and DAA-treated after IFN-based treatment failure arms at 82.4%, 88.2%, and 92.3%, respectively. HBV reactivation in HBsAg-positive CHC patients is more common and occurs earlier in those who receive DAA treatment after IFN-based treatment failure than in those with IFN-based treatment. Therefore, all patients with CHC should be tested for HBV exposure prior to DAA treatment. In addition, HBsAg positive patients, especially those among whom have previously experienced IFN-based treatment failure, should be closely monitored for HBV reactivation during DAA therapy.<\/jats:p>","DOI":"10.1371\/journal.pone.0324019","type":"journal-article","created":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:33:52Z","timestamp":1748626432000},"page":"e0324019","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["Risk of HBV reactivation in HBV\/HCV-co-infected HCV-treated patients: A single-center study"],"prefix":"10.1371","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-0615","authenticated-orcid":true,"given":"Young Joo","family":"Park","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ki Youn","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0605-6318","authenticated-orcid":true,"given":"Hyun Young","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0961-7851","authenticated-orcid":true,"given":"Jeong","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geun Am","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2025,5,30]]},"reference":[{"issue":"5","key":"pone.0324019.ref001","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jfma.2015.06.005","article-title":"Perspectives on dual hepatitis B and C infection in Taiwan","volume":"115","author":"C-J Liu","year":"2016","journal-title":"J Formos Med Assoc"},{"issue":"6","key":"pone.0324019.ref002","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1046\/j.1440-1746.2001.02494.x","article-title":"Influence of hepatitis C virus on the profiles of patients with chronic hepatitis B virus infection","volume":"16","author":"CY Dai","year":"2001","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"pone.0324019.ref003","first-page":"199","article-title":"Clinical features and treatment efficacy of peginterferon alfa plus ribavirin in chronic hepatitis C patients coinfected with hepatitis B virus","volume":"17","author":"YJ Kim","year":"2011"},{"issue":"2","key":"pone.0324019.ref004","doi-asserted-by":"crossref","first-page":"241","DOI":"10.5009\/gnl.2012.6.2.241","article-title":"The clinical and laboratory characteristics of patients with chronic hepatitis B using current or past antiviral therapy in Korea: a multi-center, nation-wide, cross-sectional epidemiologic study","volume":"6","author":"MS Choi","year":"2012","journal-title":"Gut Liver"},{"issue":"5","key":"pone.0324019.ref005","first-page":"191","article-title":"Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers","volume":"66","author":"H Senturk","year":"2008","journal-title":"Neth J Med"},{"key":"pone.0324019.ref006","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/apt.14352","article-title":"The negative impact of HBV\/HCV coinfection on cirrhosis and its consequences","volume":"46","author":"S Pol","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"4","key":"pone.0324019.ref007","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/j.1440-1746.2008.05384.x","article-title":"Hepatitis B virus\/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment","volume":"23","author":"C-J Chu","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"pone.0324019.ref008","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1053\/j.gastro.2004.01.011","article-title":"Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection","volume":"126","author":"Y-F Liaw","year":"2004","journal-title":"Gastroenterology"},{"key":"pone.0324019.ref009","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF02990102","article-title":"Hepatitis C virus superinfection in patients with chronic hepatitis B virus infection","author":"Y-F Liaw","year":"2002","journal-title":"J Gastroenterol"},{"issue":"2","key":"pone.0324019.ref010","first-page":"221","article-title":"The spectrum of HBV\/HCV coinfection: epidemiology, clinical characteristics, viralinteractions and management","volume":"28","author":"D Konstantinou","year":"2015","journal-title":"Ann Gastroenterol"},{"issue":"4","key":"pone.0324019.ref011","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrgastro.2013.216","article-title":"Management of patients with hepatitis B who require immunosuppressive therapy","volume":"11","author":"JP Hwang","year":"2014","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0324019.ref012","doi-asserted-by":"crossref","first-page":"770124","DOI":"10.3389\/fmed.2021.770124","article-title":"Hepatitis B Virus Reactivation Associated With Therapeutic Interventions","volume":"8","author":"Y Chang","year":"2022","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"pone.0324019.ref013","article-title":"Hepatitis B Virus Reactivation in Non-Liver Solid Organ Transplantation: Incidence and Risk Analysis","volume":"38","author":"C-Y Chiu","year":"2024","journal-title":"Clin Transplant"},{"issue":"7","key":"pone.0324019.ref014","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2015.03.003","article-title":"Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-\u03b3-induced protein 10 levels in HBV\/HCV-coinfected patients","volume":"21","author":"SB Wiegand","year":"2015","journal-title":"Clin Microbiol Infect"},{"issue":"8","key":"pone.0324019.ref015","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/cid\/civ475","article-title":"Editorial Commentary: Another Call to Cure Hepatitis B","volume":"61","author":"A Balagopal","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0324019.ref016","article-title":"Peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses","volume":"136","author":"C-J Liu","year":"2009","journal-title":"Gastroenterology"},{"issue":"42","key":"pone.0324019.ref017","article-title":"Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study","volume":"94","author":"M-L Yeh","year":"2015","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"pone.0324019.ref018","doi-asserted-by":"crossref","first-page":"792","DOI":"10.7326\/M17-0377","article-title":"Hepatitis B Virus Reactivation Associated With Direct-Acting Antiviral Therapy for Chronic Hepatitis C Virus: A Review of Cases Reported to the U.S. Food and Drug Administration Adverse Event Reporting System","volume":"166","author":"SJ Bersoff-Matcha","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8","key":"pone.0324019.ref019","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/apt.13985","article-title":"Hepatitis B reactivation in patients with chronic hepatitis C undergoing anti-viral therapy with an interferon-free regimen","volume":"45","author":"M-C Londo\u00f1o","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"pone.0324019.ref020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jvh.12784","article-title":"Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: Data from a national US cohort","volume":"25","author":"M Serper","year":"2018","journal-title":"J Viral Hepat"},{"issue":"5","key":"pone.0324019.ref021","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/jvh.12840","article-title":"Low incidence of hepatitis B virus reactivation and subsequent hepatitis in patients with chronic hepatitis C receiving direct-acting antiviral therapy","volume":"25","author":"A Tamori","year":"2018","journal-title":"J Viral Hepat"},{"issue":"2","key":"pone.0324019.ref022","doi-asserted-by":"crossref","first-page":"124","DOI":"10.14740\/gr971w","article-title":"Prevalence of Hepatitis B Reactivation Among Chinese Individuals With Chronic Hepatitis C Treated With Pan-Oral Direct-Acting Antivirals","volume":"11","author":"S-W Lee","year":"2018","journal-title":"Gastroenterology Res"},{"issue":"4","key":"pone.0324019.ref023","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"NA Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"1","key":"pone.0324019.ref024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12072-015-9675-4","article-title":"Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update","volume":"10","author":"SK Sarin","year":"2016","journal-title":"Hepatol Int"},{"issue":"4","key":"pone.0324019.ref025","doi-asserted-by":"crossref","first-page":"155","DOI":"10.5114\/ceh.2016.63873","article-title":"The influence of anti-HBc status on the sustained virological response rate in HCV-infected patients treated with pegylated interferon alfa 2 and ribavirin","volume":"2","author":"A Szymanek-Pasternak","year":"2016","journal-title":"Clin Exp Hepatol"},{"issue":"1","key":"pone.0324019.ref026","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.jhep.2020.01.027","article-title":"Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV\/HCV co-infection","volume":"73","author":"M-L Yeh","year":"2020","journal-title":"J Hepatol"},{"issue":"1","key":"pone.0324019.ref027","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.cgh.2016.06.023","article-title":"Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents","volume":"15","author":"C Wang","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"pone.0324019.ref028","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1111\/jgh.13771","article-title":"Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals","volume":"32","author":"M-L Yeh","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"pone.0324019.ref029","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/apt.14177","article-title":"No evidence of hepatitis B virus reactivation in patients with resolved infection treated with direct-acting antivirals for hepatitis C in a large real-world cohort","volume":"46","author":"VT M\u00fccke","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"pone.0324019.ref030","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hep.29135","article-title":"Evaluation of hepatitis B reactivation among 62,920 veterans treated with oral hepatitis C antivirals","volume":"66","author":"PS Belperio","year":"2017","journal-title":"Hepatology"},{"issue":"13","key":"pone.0324019.ref031","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1111\/hepr.12919","article-title":"Frequency of, and factors associated with, hepatitis B virus reactivation in hepatitis C patients treated with all-oral direct-acting antivirals: Analysis of a Japanese prospective cohort","volume":"47","author":"A Doi","year":"2017","journal-title":"Hepatol Res"},{"issue":"1","key":"pone.0324019.ref032","article-title":"Hepatitis B Virus Reactivation in Patients Receiving Interferon-Free Direct-Acting Antiviral Agents for Chronic Hepatitis C Virus Infection","volume":"4","author":"C-H Liu","year":"2017","journal-title":"Open Forum Infect Dis"},{"issue":"28","key":"pone.0324019.ref033","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.3748\/wjg.v24.i28.3181","article-title":"Hepatitis B reactivation in patients receiving direct-acting antiviral therapy or interferon-based therapy for hepatitis C: A systematic review and meta-analysis","volume":"24","author":"X-W Jiang","year":"2018","journal-title":"World J Gastroenterol"},{"issue":"3","key":"pone.0324019.ref034","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"MM M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"pone.0324019.ref035","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/hep.29109","article-title":"Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis","volume":"66","author":"G Chen","year":"2017","journal-title":"Hepatology"},{"issue":"9","key":"pone.0324019.ref036","article-title":"Replication Inhibition of Hepatitis B Virus and Hepatitis C Virus in Co-Infected Patients in Chinese Population","volume":"10","author":"G Yu","year":"2015","journal-title":"PLoS One"},{"issue":"26","key":"pone.0324019.ref037","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1056\/NEJMoa043470","article-title":"Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B","volume":"352","author":"GKK Lau","year":"2005","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0324019.ref038","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/01.TP.0000151661.52601.FB","article-title":"Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection","volume":"79","author":"M Onozawa","year":"2005","journal-title":"Transplantation"},{"issue":"12","key":"pone.0324019.ref039","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/jvh.12737","article-title":"Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C","volume":"24","author":"N Kawagishi","year":"2017","journal-title":"J Viral Hepat"},{"key":"pone.0324019.ref040","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcv.2017.05.021","article-title":"Hepatitis B virus reactivation among hepatitis C patients treated with direct-acting antiviral therapies in routine clinical practice","volume":"93","author":"E Loggi","year":"2017","journal-title":"J Clin Virol"},{"issue":"1","key":"pone.0324019.ref041","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/jvh.12754","article-title":"HBV reactivation in patients with HCV\/HBV cirrhosis on treatment with direct-acting antivirals","volume":"25","author":"V Calvaruso","year":"2018","journal-title":"J Viral Hepat"},{"issue":"10","key":"pone.0324019.ref042","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/14787210.2020.1782189","article-title":"Low risk of HBV reactivation in a large European cohort of HCV\/HBV coinfected patients treated with DAA","volume":"18","author":"J Jaroszewicz","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"5","key":"pone.0324019.ref043","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1159\/000521298","article-title":"Hepatitis B Reactivation in Patients Treated with Direct-Acting Antivirals for Hepatitis C","volume":"40","author":"B Toka","year":"2022","journal-title":"Dig Dis"},{"issue":"2","key":"pone.0324019.ref044","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3350\/cmh.2022.0084","article-title":"KASL clinical practice guidelines for management of chronic hepatitis B","volume":"28","author":"(KASL) Korean Association for the Study of the Liver","year":"2022","journal-title":"Clin Mol Hepatol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324019","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T17:34:18Z","timestamp":1748626458000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0324019"}},"subtitle":[],"editor":[{"given":"Riccardo","family":"Nevola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2025,5,30]]},"references-count":44,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,5,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0324019","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,30]]}}}